For Novartis, No Relax’in On Serelaxin: More Trials Likely
This article was originally published in Pharmaceutical Approvals Monthly
Novartis released mixed Phase III data on its heart failure candidate at the American Heart Association Scientific Sessions, showing the drug reduced symptoms of acute heart failure but failed to demonstrate an improvement on a second endpoint, cardiovascular death and hospital stays at 60 days.
You may also be interested in...
The unexpected delay of U.S. generic competition to Diovan helped pad some of the impact felt by Novartis from the loss of exclusivity on the blockbuster hypertension drug. Still, the impact of generics weighed on Novartis’ third quarter sales, and the delay is only a temporary reprieve of the inevitable sales erosion.
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.